A Response to: Letter to the Editor Regarding A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study

Rheumatol Ther. 2022 Feb;9(1):309-311. doi: 10.1007/s40744-021-00387-9. Epub 2021 Nov 10.

¹ Internal Medicine, Rheumatology Division, Metroplex Clinical Research Center, Dallas, TX, USA. [email protected].
² Scipher Medicine, Waltham, MA, USA.

No abstract available

Keywords: Molecular signature response classifier; Precision medicine; Rheumatoid arthritis.

Publication types